Piramal Pharma plans to double its turnover to $2 billion by 2030, focusing on its CDMO business and high-growth sectors like complex hospital generics and consumer healthcare. The company aims for significant revenue growth and improved EBITDA margins through strategic investments, expansions, and leveraging cost-efficient manufacturing infrastructure in India.